Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

13.45 +0.33 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Stocks That Hit 52-Week Lows On Monday
  Monday saw 33 companies set new 52-week lows. 
Via Benzinga
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace: Q2 Earnings Insights
  NeuroPace (NASDAQ:NPCE) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Expert Ratings For NeuroPace
Analysts have provided the following ratings for NeuroPace (NASDAQ:NPCE) within the last quarter: 
Via Benzinga
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)
From NeuroPace, Inc.
Via Business Wire
NeuroPace's Return On Capital Employed Insights
NeuroPace (NASDAQ:NPCE) brought in sales totaling $10.20 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.72%, resulting in a loss of $12.69 million. 
Via Benzinga
5 Analysts Have This to Say About NeuroPace
Over the past 3 months, 5 analysts have published their opinion on NeuroPace (NASDAQ:NPCE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Bear Of The Day: NeuroPace (NPCE)
NeuroPace is a $200 million commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy. 
Via Talk Markets
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Recap: NeuroPace Q1 Earnings
NeuroPace (NASDAQ:NPCE) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NeuroPace missed estimated earnings... 
Via Benzinga
NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents
From NeuroPace, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 18 companies made new 52-week lows. Noteable 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) is the largest company in terms of market... 
Via Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
NeuroPace, Inc. (NPCE) Q3 2021 Earnings Call Transcript
NPCE earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
Looking Into NeuroPace's Return On Capital Employed
Benzinga Pro data, NeuroPace (NASDAQ:NPCE) reported Q2 sales of $12.63 million. Earnings fell to a loss of $4.61 million, resulting in a 18.87% decrease from last quarter. In Q1... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.